(New York Times) – The Federal Trade Commission announced on Wednesday that it had reached a settlement with Cigna’s Express Scripts, one of the nation’s largest pharmacy benefit managers, over its role in driving up insulin prices.

Express Scripts will not pay a fine or face a financial penalty as part of the settlement and did not admit to any wrongdoing. But the company agreed to a range of changes to its business model. (Read More)